Drugs / G-Pen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01972152 | Oct 2013 → Feb 2014 | hypoglycemia | Xeris Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-05-21 | Xeris Pharmaceuticals | Results Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting xerispharma.com ↗
88% of subjects were able to successfully administer the G-Pen TM auto-injector versus only 31% of subjects successfully administering currently available glucagon rescue kits |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-05-21 | Xeris Pharmaceuticals | Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting xerispharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-Pen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01972152 ↗ |
| Known as | glucagon injection | “G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection” NCT01972152 ↗ |
| Route | Subcutaneous | “G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection” NCT01972152 ↗ |